Australia's genetic discrimination ban: An opportunity for genomics and preventive health

The Australian government's recent legislative ban on the use of genetic test results in life insurance underwriting is, on one level, insurance sector reform. Its significance, however, extends well beyond the insurance industry, representing a shift in policy dialogue about genomics and healthcare.

The legislation removes a longstanding barrier to participation in genetic testing and genomic research at a time when genomics is becoming increasingly important for disease prevention and population health (see BioNews 1335).

For many years, genetic discrimination concerns have cast a shadow over genomic medicine in Australia. Frequently, people choose not to have genetic testing that could save their lives, or to participate in genomic research, because of concerns about life insurance implications. Clinicians and researchers have consistently reported this as the most significant issue causing people to decline genetic testing, creating public health impacts that required regulatory reform.

Until now, Australian life insurers could legally ask applicants to disclose genetic test results and use those results in underwriting decisions. Individuals found to carry genetic variants associated with increased disease risk could be charged higher premiums, have conditions excluded from cover or be denied insurance altogether. While these practices were allowed within existing insurance and anti-discrimination frameworks, it meant Australians' access to potentially life-saving health information came with possible financial harms. The new legislation changes that.

From 8 October 2026, life insurers will no longer be able to use genetic test results that show risk of future disease in their underwriting processes. Existing diagnoses and family history of disease can still be taken into account, but the ban draws a protective boundary around a particular category of information: genetic test results that predict future health risks.

The most important outcome of the Australian legislation is that it protects the decision to undergo genetic testing and be proactive about health. Individuals who choose to learn about inherited risks of cancer, cardiovascular disease or other conditions will no longer be penalised for choosing to know something that could help them prevent disease or seek earlier treatment.

The reform also highlights a difference between how Australia approaches health insurance and life insurance. Australia's private health insurance system is community-rated, meaning that although health insurers can apply waiting periods for pre-existing conditions, they cannot vary premiums or deny cover on the basis of health status or risk, including on the basis of genetics.

Life insurance remains risk-rated and continues to rely on underwriting to assess individual risk. The new legislation does not alter that fundamental distinction, but recognises that predictive genetic information requires specific protections because of the broader health consequences that can arise when people are discouraged from accessing it.

For much of its history, clinical genetics has focused on explaining why disease had already occurred, and sometimes the best way to treat it. However, genomic medicine is now being used to identify risk before disease develops; identifying individuals at increased risk of hereditary cancers, cardiovascular conditions and other disorders for which surveillance, preventive interventions or earlier treatment can improve outcomes. The goal is no longer simply to explain disease, but to prevent it.

This shift is also reflected in growing interest in population genomic screening. Several countries are exploring approaches that offer DNA screening at the population level, in order to identify medically actionable disease risks before symptoms appear. These programmes are demonstrating that earlier knowledge can create opportunities for prevention and reduce the burden of disease across the population.

One example is DNA Screen, the DNA screening study I co-lead at Monash University, which tested approximately 10,000 young adults in the general population for high genetic risk of cancer and heart disease. Even testing only ten genes across three conditions, we found about one in 50 people (two percent) had a DNA variant conferring very high risk of early-onset disease that was preventable or treatable early.

The effectiveness of population genomic screening programmes into the future depends on public trust and participation. If people decline testing because of concerns about downstream consequences, opportunities for prevention may be missed. Relatives who could benefit from testing may remain unidentified, and research participation may fall.

In DNA Screen, more than half of the people we surveyed who initially signed up and then did not complete participation in the programme cited insurance concerns when asked for their reasons. The effect of these discrimination fears extends beyond individual decision-making, influencing the broader ability of healthcare systems to realise the benefits of genomic medicine.

Viewed from the perspective of preventive health policy, concerns about genetic discrimination have never been solely about insurance. They have been about creating conditions in which genomic medicine can function effectively as part of routine preventive healthcare.

Australia is not the first country to address genetic discrimination, but its approach is notable because it replaces partial industry arrangements with total legislated protections. At a time when many countries continue to debate how predictive genetic information should be regulated, the reforms provide a clear statement that access to potentially beneficial genetic information should not create insurance disadvantages for individuals who choose to be tested.

The legislation does not resolve every challenge associated with genomic medicine. Questions relating to privacy, data governance, data sharing and the interpretation of increasingly complex genomic information remain. Ensuring that genomic technologies are implemented fairly and responsibly will require ongoing attention from policymakers, health professionals and researchers.

Nevertheless, the legislation creates an important opportunity to move towards population genomic screening at scale. It recognises that genetic testing is becoming an important tool for prevention, early intervention and population health. As genomics becomes more deeply embedded in routine healthcare, protection of individuals' genetic information will become increasingly important.

Australia's genetic discrimination ban does not guarantee the success of genomic medicine, but it removes one of the most persistent barriers standing in its way.